These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23952194)

  • 1. Bevacizumab for the treatment of glioblastoma.
    Chowdhary S; Chamberlain M
    Expert Rev Neurother; 2013 Aug; 13(8):937-49. PubMed ID: 23952194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC
    Expert Rev Neurother; 2012 Aug; 12(8):929-36. PubMed ID: 23002937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-angiogenic strategies in glioblastoma].
    Guillamo JS
    Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in glioblastoma multiforme.
    Specenier P
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
    Chamberlain MC
    Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab as first-line therapy for glioblastoma.
    Piccioni D; Lai A; Nghiemphu P; Cloughesy T
    Future Oncol; 2012 Aug; 8(8):929-38. PubMed ID: 22894667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
    Seystahl K; Weller M
    Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.
    Khasraw M; Ameratunga M; Grommes C
    Expert Opin Biol Ther; 2014 May; 14(5):729-40. PubMed ID: 24655021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of antiangiogenic treatment in glioblastoma.
    Chinot OL; Reardon DA
    Curr Opin Neurol; 2014 Dec; 27(6):675-82. PubMed ID: 25313693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
    Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
    Chinot OL
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on bevacizumab and other angiogenesis inhibitors for brain cancer.
    Rinne ML; Lee EQ; Nayak L; Norden AD; Beroukhim R; Wen PY; Reardon DA
    Expert Opin Emerg Drugs; 2013 Jun; 18(2):137-53. PubMed ID: 23668489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-angiogenic therapy for malignant glioma].
    Nagane M
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):141-7. PubMed ID: 24743191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.
    Field KM; Jordan JT; Wen PY; Rosenthal MA; Reardon DA
    Cancer; 2015 Apr; 121(7):997-1007. PubMed ID: 25263092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
    Narita Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent high-grade glioma: a diagnostic and therapeutic challenge.
    Walbert T; Mikkelsen T
    Expert Rev Neurother; 2011 Apr; 11(4):509-18. PubMed ID: 21469924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.